Ultragenyx Pharmaceutical Inc. is facing a federal securities class action lawsuit following allegations that the company and its executives made false and misleading statements regarding the effects of setrusumab in patients with various types of Osteogenesis Imperfecta. The complaint asserts that Ultragenyx created a false impression about the reliability of their Phase III Orbit study results, downplaying the risks associated with basing interim analysis benchmarks on Phase II data that lacked a placebo control. After these concerns came to light, the company's stock price fell by more than 42 percent. Investors who suffered significant losses between August 3, 2023 and December 26, 2025 have until April 6, 2026 to seek appointment as lead plaintiff in the ongoing litigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602150755PRIMZONEFULLFEED9654258) on February 15, 2026, and is solely responsible for the information contained therein.